AI Summary
The content discusses how serum glial fibrillary acidic protein (sGFAP) is becoming a valuable biomarker for predicting disability in patients with multiple sclerosis (MS). This biomarker, along with serum neurofilament light chain (sNFl), can provide unique insights into the progression of MS and its impact on patient outcomes.
Serum glial fibrillary acidic protein (sGFAP) is quickly maturing as a biomarker to predict disability in patients with multiple sclerosis (MS).
MDedge News